To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...
Medical Xpress on MSN7d
Research Pinpoints Weakness in Lung Cancer’s DefensesResearchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
7d
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...
First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER trial. The study ...
Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).
Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...
Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money.
The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback